Metabolic and renal adverse effects of antiretroviral therapy in HIV-infected children and adolescents

Pediatric Infectious Disease Journal

Volumn 34, Issue , 2015, Pages S36-S43

  Fortuny, Clàudia ^a   Deyà Martínez, Ángela ^a   Chiappini, Elena ^b   Galli, Luisa ^b   De Martino, Maurizio ^b   Noguera Julian, Antoni ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antiretrovirals; Human immunodeficiency virus; Metabolic; Nephropathy; Pediatrics

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ANTIVIRAL THERAPY; ARTICLE; BODY FAT DISTRIBUTION; BONE DENSITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHILD; DYSLIPIDEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; KIDNEY DISEASE; LIPODYSTROPHY; METABOLIC DISORDER; MITOCHONDRIAL TOXICITY; MORBIDITY; NEPHROTOXICITY; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VULNERABLE POPULATION; ADVERSE EFFECTS; CHEMICALLY INDUCED; DRUG EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; METABOLISM; MITOCHONDRION;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; METABOLIC DISEASES; MITOCHONDRIA;

EID: 84921914323     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000663     Document Type: Article

References (110)

1. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS. 2004;18:1443-1451.
2. Rosso R, Parodi A, d'Annunzio G, et al. Evaluation of insulin resistance in a cohort of HIV-infected youth. Eur J Endocrinol. 2007;157:655-659.
3. Aurpibul L, Puthanakit T, Lee B, et al. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Antivir Ther. 2007;12:1247-1254.
4. Brewinski M, Megazzini K, Hance LF, et al; NISDI Pediatric Study Group 2010. Dyslipidemia in a cohort of HIV-infected Latin American children receiving highly active antiretroviral therapy. J Trop Pediatr. 2011;57:324-332.
5. Dapena M, Jiménez B, Noguera-Julian A, et al. Metabolic disorders in vertically HIV-infected children: future adults at risk for cardiovascular disease. J Pediatr Endocrinol Metab. 2012;25:529-535.
6. Alam N, Cortina-Borja M, Goetghebuer T, et al; European Paediatric HIV and Lipodystrophy Study Group in EuroCoord. Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors. J Acquir Immune Defic Syndr. 2012;59:314-324.
7. Piloya T, Bakeera-Kitaka S, Kekitiinwa A, et al. Lipodystrophy among HIVinfected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study. J Int AIDS Soc. 2012;15:17427.
8. Hazra R, Hance LF, Monteiro JP, et al; NISDI Pediatric Study Group 2012. Insulin resistance and glucose and lipid concentrations in a cohort of perinatally HIV-infected Latin American children. Pediatr Infect Dis J. 2013;32:757-759.
9. Kinabo GD, Sprengers M, Msuya LJ, et al. Prevalence of lipodystrophy in HIV-infected children in Tanzania on highly active antiretroviral therapy. Pediatr Infect Dis J. 2013;32:39-44.
10. Welch S, Sharland M, Lyall EG, et al; PENTA Steering Committee. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med. 2009;10:591-613.
11. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf. Accessed June 24, 2014.
12. World Health Organization. Antiretroviral therapy of HIV infection in infants and children: towards universal access: recommendations for a public health approach-2010 revision. Available at: http://www.who.int/hiv/pub/paediatric/infants2010/en/. Accessed June 24, 2014.
13. Andiman WA, Chernoff MC, Mitchell C, et al; PACTG iDACS 617 Study Team. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. Pediatr Infect Dis J. 2009;28:619-625.
14. Bunupuradah T, Puthanakit T, Fahey P, et al; TApHOD. Second-line protease inhibitor-based HAART after failing non-nucleoside reverse transcriptase inhibitor-based regimens in Asian HIV-infected children. Antivir Ther. 2013;18:591-598.
15. Langat A, Benki-Nugent S, Wamalwa D, et al. Lipid changes in Kenyan HIV-1-infected infants initiating highly active antiretroviral therapy by 1 year of age. Pediatr Infect Dis J. 2013;32:e298-e304.
16. Maagaard A, Holberg-Petersen M, Kvittingen EA, et al. Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naïve patients. HIV Med. 2006;7:53-58.
17. Côté HC. Possible ways nucleoside analogues can affect mitochondrial DNA content and gene expression during HIV therapy. AntivirTher. 2005;10(suppl 2):3-11.
18. Foster C, Lyall H. HIV and mitochondrial toxicity in children. J Antimicrob Chemother. 2008;61:8-12.
19. Koczor CA, Lewis W. Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA. Expert Opin Drug Metab Toxicol. 2010;6:1493-1504.
20. Côté HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med. 2002;346:811-820.
21. Dowell P, Flexner C, Kwiterovich PO, et al. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem. 2000;275:41325-41332.
22. Morén C, Noguera-Julian A, Rovira N, et al. Mitochondrial impact of human immunodeficiency virus and antiretrovirals on infected pediatric patients with or without lipodystrophy. Pediatr Infect Dis J. 2011;30:992-995.
23. Morén C, Noguera-Julian A, Garrabou G, et al. Mitochondrial evolution in HIV-infected children receiving first-or second-generation nucleoside analogues. J Acquir Immune Defic Syndr. 2012;60:111-116.
24. Saitoh A, Haas RH, Naviaux RK, et al. Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. Antimicrob Agents Chemother. 2008;52:2825-2830.
25. Noguera A, Fortuny C, Sanchez E, et al. Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment. Pediatr Infect Dis J. 2003;22:778-782.
26. Desai N, Mathur M, Weedon J. Lactate levels in children with HIV/AIDS on highly active antiretroviral therapy. AIDS. 2003;17:1565-1568.
27. Church JA, Mitchell WG, Gonzalez-Gomez I, et al. Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIVinfected child treated with combination antiretroviral therapy. J Pediatr. 2001;138:748-751.
28. Rosso R, Di Biagio A, Ferrazin A, et al. Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection. Pediatr Infect Dis J. 2003;22:668-670.
29. Rey C, Prieto S, Medina A, et al. Fatal lactic acidosis during antiretroviral therapy. Pediatr Crit Care Med. 2003;4:485-487.
30. Shah I. Lactic acidosis in HIV infected children due to antiretroviral therapy. Indian Pediatr. 2005;42:1051-1052.
31. Tukei VJ, Asiimwe A, Maganda A, et al. Safety and tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda. J Acquir Immune Defic Syndr. 2012;59:274-280.
32. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354:1084-1089.
33. Noguera A, Fortuny C, Muñoz-Almagro C, et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics. 2004;114:e598-e603.
34. Brogly SB, Ylitalo N, Mofenson LM, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS. 2007;21:929-938.
35. Soler-Palacín P, Ciria Calavia L, Polo Rodriguez R, et al. Recomendaciones CEVIHP/SEIP/AEP/SPNS para el seguimiento del paciente pediátrico infectado por el Virus de la Inmunodeficiencia Humana (VIH). Available at: http://www.seipweb.es/images/site/pdf/docu-oficiales/6.pdf. Accessed June 24, 2014.
36. Innes S, Cotton MF, Haubrich R, et al. High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study. BMC Pediatr. 2012;12:183.
37. Tungsiripat M, O'Riordan MA, Storer N, et al. Subjective clinical lipoatrophy assessment correlates with DEXA-measured limb fat. HIV Clin Trials. 2009;10:314-319.
38. Viganò A, Brambilla P, Cafarelli L, et al. Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz. Antivir Ther. 2007;12:297-302.
39. Aurpibul L, Puthanakit T, Taejaroenkul S, et al. Recovery from lipodystrophy in HIV-infected children after substitution of stavudine with zidovudine in a non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr Infect Dis J. 2012;31:384-388.
40. Sawawiboon N, Wittawatmongkol O, Phongsamart W, et al. Lipodystrophy and reversal of facial lipoatrophy in perinatally HIV-infected children and adolescents after discontinuation of stavudine. Int J STD AIDS. 2012;23:497-501.
41. McComsey G, Bhumbra N, Ma JF, et al; First Pediatric Switch Study. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics. 2003;111:e275-e281.
42. Gonzalez-Tome MI, Amador JT, Peña MJ, et al. Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children. BMC Infect Dis. 2008;8:144.
43. Dollfus C, Blanche S, Trocme N, et al. Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents. HIV Med. 2009;10:263-268.
44. Fundación para la Formación e Información sobre Tratamientos en el VIH/sida (FIT). Surgical treatment of lipodystrophy associated with HIV-infection: conclusions of a multidisciplinary meeting. Enferm Infecc Microbiol Clin. 2007;25:324-328.
45. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Available at: http://www.nhlbi.nih.gov/health-pro/guidelines/current/cardiovascularhealth-pediatric-guidelines/summary.htm#chap9. Accessed August 9, 2014.
46. Farley J, Gona P, Crain M, et al; Pediatric AIDS Clinical Trials Group Study 219C Team. Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C. J Acquir Immune Defic Syndr. 2005;38:480-487.
47. Chantry CJ, Hughes MD, Alvero C, et al; PACTG 1010 Team. Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy. Pediatrics. 2008;122:e129-e138.
48. Kanjanavanit S, Puthanakit T, Vibol U, et al; PREDICT study group. High prevalence of lipid abnormalities among antiretroviral-naive HIV-infected Asian children with mild-to-moderate immunosuppression. Antivir Ther. 2011;16:1351-1355.
49. Jacobson DL, Williams P, Tassiopoulos K, et al. Clinical management and follow-up of hypercholesterolemia among perinatally HIV-infected children enrolled in the PACTG 219C study. J Acquir Immune Defic Syndr. 2011;57:413-420.
50. Viganò A, Aldrovandi GM, Giacomet V, et al. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. Antivir Ther. 2005;10:917-924.
51. Strehlau R, Coovadia A, Abrams EJ, et al. Lipid profiles in young HIVinfected children initiating and changing antiretroviral therapy. J Acquir Immune Defic Syndr. 2012;60:369-376.
52. Arpadi S, Shiau S, Strehlau R, et al. Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arch Dis Child. 2013;98:258-264.
53. Rhoads MP, Lanigan J, Smith CJ, et al. Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV. J Acquir Immune Defic Syndr. 2011;57:404-412.
54. Lee B, Aurpibul L, Sirisanthana V, et al. Low prevalence of insulin resistance among HIV-infected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand. HIV Med. 2009;10:72-78.
55. Aldrovandi GM, Lindsey JC, Jacobson DL, et al; Pediatric AIDS Clinical Trials Group P1045 team. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS. 2009;23:661-672.
56. Geffner ME, Patel K, Miller TL, et al; Pediatric HIV/AIDS Cohort Study. Factors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the pediatric HIV/AIDS cohort study. Horm Res Paediatr. 2011;76:386-391.
57. Dimock D, Thomas V, Cushing A, et al. Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhood. Metabolism. 2011;60:874-880.
58. Deyà-Martínez A, Noguera-Julian A, Vila J, et al. The role of albuminuria in the follow-up of HIV-infected pediatric patients. Pediatr Nephrol. 2014;29:1561-1566.
59. Dejkhamron P, Unachak K, Aurpibul L, et al. Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavirbased highly active antiretroviral therapy. J Pediatr Endocrinol Metab. 2014;27:403-412.
60. Mur A, Seidel V, López-Vílchez MA, et al. Acanthosis nigricans as an adverse effect of highly active antiretroviral therapy in an adolescent girl with human immunodeficiency virus infection. Pediatr Infect Dis J. 2005;24:742-743.
61. Viganò A, Brambilla P, Pattarino G, et al. Long-term evaluation of glucose homeostasis in a cohort of HAART-treated HIV-infected children: a longitudinal, observational cohort study. Clin Drug Investig. 2009;29:101-109.
62. Bavinger C, Bendavid E, Niehaus K, et al. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One. 2013;8:e59551.
63. Post WS, Budoff M, Kingsley L, et al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med. 2014;160:458-467.
64. Jacobson DL, Patel K, Siberry GK, et al; Pediatric HIV/AIDS Cohort Study. Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study. Am J Clin Nutr. 2011;94:1485-1495.
65. Morrison JA, Friedman LA, Gray-McGuire C. Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: the Princeton Lipid Research Clinics Follow-up Study. Pediatrics. 2007;120:340-345.
66. Shear CL, Freedman DS, Burke GL, et al. Body fat patterning and blood pressure in children and young adults. The Bogalusa Heart Study. Hypertension. 1987;9:236-244.
67. Freedman DS, Serdula MK, Srinivasan SR, et al. Relation of circumferences and skinfold thicknesses to lipid and insulin concentrations in children and adolescents: the Bogalusa Heart Study. Am J Clin Nutr. 1999;69:308-317.
68. Kuller LH, Tracy R, Belloso W, et al; INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.
69. McMahan CA, Gidding SS, Fayad ZA, et al. Risk scores predict atherosclerotic lesions in young people. Arch Intern Med. 2005;165:883-890.
70. Patel K, Wang J, Jacobson DL, et al; Pediatric HIV/AIDS Cohort Study (PHACS). Aggregate risk of cardiovascular disease among adolescents perinatally infected with the human immunodeficiency virus. Circulation. 2014;129:1204-1212.
71. Giuliano Ide C, de Freitas SF, de Souza M, et al. Subclinic atherosclerosis and cardiovascular risk factors in HIV-infected children: PERI study. Coron Artery Dis. 2008;19:167-172.
72. Charakida M, Loukogeorgakis SP, Okorie MI, et al. Increased arterial stiffness in HIV-infected children: risk factors and antiretroviral therapy. Antivir Ther. 2009;14:1075-1079.
73. Ross AC, Storer N, O'Riordan MA, et al. Longitudinal changes in carotid intima-media thickness and cardiovascular risk factors in human immunodeficiency virus-infected children and young adults compared with healthy controls. Pediatr Infect Dis J. 2010;29:634-638.
74. Sainz T,álvarez-Fuente M, Navarro ML, et al; Madrid Cohort of HIVinfected children and adolescents integrated in the Pediatric branch of the Spanish National AIDS Network (CoRISPE). Subclinical atherosclerosis and markers of immune activation in HIV-infected children and adolescents: the CaroVIH Study. J Acquir Immune Defic Syndr. 2014;65:42-49.
75. Miller TI, Borkowsky W, DiMeglio LA, et al; Pediatric HIV/AIDS Cohort Study (PHACS). Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med. 2012;13:264-275.
76. Mikhail IJ, Purdy JB, Dimock DS, et al. High rate of coronary artery abnormalities in adolescents and young adults infected with human immunodeficiency virus early in life. Pediatr Infect Dis J. 2011;30:710-712.
77. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20:2165-2174.
78. Shiau S, Broun EC, Arpadi SM, et al. Incident fractures in HIV-infected individuals: a systematic review and meta-analysis. AIDS. 2013;27:1949-1957.
79. Duvivier C, Kolta S, Assoumou L, et al; ANRS 121 Hippocampe study group. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS. 2009;23:817-824.
80. Reynes J, Trinh R, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses. 2013;29:256-265.
81. Jacobson DL, Lindsey JC, Gordon CM, et al; Pediatric AIDS Clinical Trials Group P1045 team. Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. AIDS. 2010;24:687-696.
82. Puthanakit T, Saksawad R, Bunupuradah T, et al. Prevalence and risk factors of low bone mineral density among perinatally HIV-infected Thai adolescents receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2012;61:477-483.
83. Schtscherbyna A, Pinheiro MF, Mendonça LM, et al. Factors associated with low bone mineral density in a Brazilian cohort of vertically HIV-infected adolescents. Int J Infect Dis. 2012;16:e872-e878.
84. DiMeglio LA, Wang J, Siberry GK, et al; Pediatric HIVAIDS Cohort Study (PHACS). Bone mineral density in children and adolescents with perinatal HIV infection. AIDS. 2013;27:211-220.
85. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics. 2006;118:e711-e718.
86. Rutstein R, Downes A, Zemel B, et al. Vitamin D status in children and young adults with perinatally acquired HIV infection. Clin Nutr. 2011;30:624-628.
87. Madrid L, DeyàÀ, Noguera-Julian A, et al. Normal levels of vitamin D among HIV-infected Catalan pediatric patients. J Acquir Immune Defic Syndr. 2012;61:e18-e19.
88. Eckard AR, Tangpricha V, Seydafkan S, et al. The relationship between vitamin D status and HIV-related complications in HIV-infected children and young adults. Pediatr Infect Dis J. 2013;32:1224-1229.
89. Meyzer C, Frange P, Chappuy H, et al. Vitamin D deficiency and insufficiency in HIV-infected children and young adults. Pediatr Infect Dis J. 2013;32:1240-1244.
90. Arpadi SM, McMahon D, Abrams EJ, et al. Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. Pediatrics. 2009;123:e121-e126.
91. Kakalia S, Sochett EB, Stephens D, et al. Vitamin D supplementation and CD4 count in children infected with human immunodeficiency virus. J Pediatr. 2011;159:951-957.
92. Arpadi SM, McMahon DJ, Abrams EJ, et al. Effect of supplementation with cholecalciferol and calcium on 2-y bone mass accrual in HIV-infected children and adolescents: a randomized clinical trial. Am J Clin Nutr. 2012;95:678-685.
93. Giacomet V, Vigano A, Manfredini V, et al. Cholecalciferol supplementation in HIV-infected youth with vitamin D insufficiency: effects on vitamin D status and T-cell phenotype: a randomized controlled trial. HIV Clin Trials. 2013;14:51-60.
94. Siberry GK, Li H, Jacobson D; Pediatric AIDS Clinical Trials Group (PACTG) 219/219C Study. Fracture risk by HIV infection status in perinatally HIV-exposed children. AIDS Res Hum Retroviruses. 2012;28:247-250.
95. Soler Palacin P, Torrent A, Rossich R, et al. Osteoporosis and multiple fractures in an antiretroviral-naive, HIV-positive child. J Pediatr Endocrinol Metab. 2007;20:933-938.
96. Fortuny C, Noguera A, Alsina L, et al. Long-term use of bisphosphonates in the treatment of HIV-related bone pain in perinatally infected pediatric patients. AIDS. 2008;22:1888-1890.
97. Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol. 2013;24:1519-1527.
98. Soler-Palacín P, Melendo S, Noguera-Julian A, et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. AIDS. 2011;25:171-176.
99. Judd A, Boyd KL, Stöhr W, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS. 2010;24:525-534.
100. Purswani M, Patel K, Kopp JB, et al. Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J. 2013;32:495-500.
101. Hussain S, Khayat A, Tolaymat A, Rathore MH. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatr Nephrol. 2006;21:1034-1036.
102. Hawkins S, Ball C. Adverse events experienced by three children taking tenofovir and didanosine in combination. HIV Med. 2007;8:411.
103. Wood SM, Shah SS, Steenhoff AP, Meyers KE, Kaplan BS, Rutstein RM. Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males. AIDS Patient Care STDS. 2009;23:1-4.
104. Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovirrelated renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr. 2010;55:78-81.
105. van Rossum AM, Dieleman JP, Fraaij PL, et al. Indinavir-associated asymptomatic nephrolithiasis and renal cortex atrophy in two HIV-1 infected children. AIDS. 2001;15:1745-1747.
106. van Rossum AM, Dieleman JP, Fraaij PL, et al. Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir. Pediatrics. 2002;110(2 Pt 1):e19.
107. Hamada Y, Nishijima T, Watanabe K, et al. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis. 2012;55:1262-1269.
108. Green ST, McKendrick MW, Schmid ML, et al. Renal calculi developing de novo in a patient taking saquinavir. Int J STD AIDS. 1998;9:555.
109. Engeler DS, John H, Rentsch KM, et al. Nelfinavir urinary stones. J Urol. 2002;167:1384-1385.
110. Feicke A, Rentsch KM, Oertle D, et al. Same patient, new stone composition: amprenavir urinary stone. Antivir Ther. 2008;13:733-734.